Pseudomonas aeruginosa: Arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies

Future Microbiology

Volumn 10, Issue 10, 2015, Pages 1683-1706

  El Zowalaty, Mohamed E ^a,b   Al Thani, Asmaa A ^b,c   Webster, Thomas J ^d,e   El Zowalaty, Ahmed E ^f   Schweizer, Herbert P ^g,h   Nasrallah, Gheyath K ^b,c   Marei, Hany E ^b   Ashour, Hossam M ^i,j  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Qatar University   (Qatar)

^c Qatar University   (Qatar)

^d Northeastern University   (United States)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^f UNIVERSITY OF GEORGIA   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ CAIRO UNIVERSITY   (Egypt)

^j WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

antibiotics; antimicrobial; carbapenemases; decoys; efflux; gold; impermeability; mechanisms; multidrug; nanoantimicrobial; nanoparticles; nanostars; pandrug; phage therapy; polymersomes; Pseudomonas aeruginosa; pumps; resistance; vaccines; vecoys; virus; lactamases

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BIOCIDE; MULTIDRUG RESISTANCE PROTEIN; POLYMYXIN B; PSEUDOMONAS VACCINE; QUINOLONE DERIVATIVE; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; DRUG EFFICACY; DRUG EXPOSURE; ENZYME INACTIVATION; ENZYME MODIFICATION; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PHAGE THERAPY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; THERAPY; CROSS INFECTION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS INFECTIONS; TRANSPORT AT THE CELLULAR LEVEL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BIOLOGICAL TRANSPORT; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84945316857     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.48     Document Type: Review

References (226)

1. Pitt T. Pseudomonas, Burkholderia and related genera. Topley and Wilson's microbiology and microbial infections, vol. 2, 9th Ed. Balows A, Duerden BI (Eds). 1120-1127, Oxford University Press NY, USA (1998
2. Gessard MC. Sur la fonction fluorescigene des microbes. Ann. Inst. Pasteur Paris 8, 801-823 (1892
3. Gessard C. On the blue and green coloration that appears on bandages. Rev. Infect. Dis.6(Suppl. 3), S775-S776 (1894
4. Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2(9), 1051-1060 (2000
5. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22(4), 582-610 (2009
6. Walker TS, Bais HP, Deziel E et al. Pseudomonas aeruginosa-plant root interactions. Pathogenicity, biofilm formation, and root exudation. Plant Physiol. 134(1), 320-331 (2004
7. Iglewski BH. Pseudomonas. In: Medical Microbiology. Baron S (Ed.). Galveston (TX). University of Texas Medical Branch at Galveston, TX, USA (1996
8. Stover C, Pham X, Erwin A et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406(6799), 959-964 (2000
9. Ohmagari N, Hanna H, Graviss L et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104(1), 205-212 (2005
10. Winsor GL, Lam DK, Fleming L et al. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res.39, D596-D600 (2011
11. Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5(2), 279-313 (1983
12. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67(3), 351-368 (2007
13. Nicas T, Iglewski B. Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa. Antibiot. Chemother. 36, 40-48 (1984
14. Smith RS, Iglewski BH. P. aeruginosa quorum-sensing systems and virulence. Curr. Opin. Microbiol. 6(1), 56-60 (2003
15. Nicas TI, Iglewski BH. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Canad. J. Microbiol. 31(4), 387-392 (1985
16. Kipnis E, Sawa T, Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36(2), 78-91 (2006
17. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol. 12(1), 61-66 (2009
18. Strateva T, Mitov I. Contribution of an arsenal of virulence factors to pathogenesis of Pseudomonas aeruginosa infections. Ann. Microbiol. 61(4), 717-732 (2011
19. Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev. Infect. Dis. 5(2), 314-321 (1983
20. Pena C, Cabot G, Gomez-Zorrilla S et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin. Infect. Dis. 60(4), 539-548 (2015
21. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 7(9), 654-665 (2009
22. Pollack M. Pseudomonas aeruginosa. In: Principles and practices of infectious diseases. Mandell Gl BJ, Dolin R (Eds). Churchill Livingstone, PA, USA, 2310-2335 (2000
23. Wu DC, Chan WW, Metelitsa AI, Fiorillo L, Lin AN. Pseudomonas skin infection. Am. J. Clin. Dermatol. 12(3), 157-169 (2011
24. Tredget EE, Shankowsky HA, Rennie R, Burrell RE, Logsetty S. Pseudomonas infections in the thermally injured patient. Burns 30(1), 3-26 (2004
25. Tawfik AF, Shibl AM, Aljohi MA, Altammami MA, Al-Agamy MH. Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates. Burns 38(6), 855-860 (2012
26. Keene WE, Markum AC, Samadpour M. Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage. JAMA 291(8), 981-985 (2004
27. Moolenaar RL, Crutcher JM, Joaquin VHS et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission?. Infect. Control Hosp. Epidemiol. 21(2), 80-85 (2000
28. Al-Mulla NA, Taj-Aldeen SJ, El Shafie S, Janahi M, Al-Nasser AA, Chandra P. Bacterial bloodstream infections and antimicrobial susceptibility pattern in pediatric hematology/oncology patients after anticancer chemotherapy. Infect. Drug Res. 7, 289-299 (2014
29. Marin M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratala J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine 93(3), 143-149 (2014
30. Kerr KG, Snelling AM. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect.73(4), 338-344 (2009
31. Fleming A. On the antibacterial action of cultures of a Penicillium with special reference to their use in the isolation of B. influenzae. Br. J. Exper. Path. 10, 226-236 (1929
32. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43(3), 239-243 (2002
33. Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front. Microbiol. 4, 422 (2013
34. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat. 3(4), 247-255 (2000
35. Blandino G, Marchese A, Ardito F et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections. Int. J. Antimicrob. Agents 24(5), 515-518 (2004
36. Manno G, Cruciani M, Romano L. et al. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Int. J. Antimicrob. Agents 25(3), 193-197 (2005
37. Romao CMCPA, Faria YND, Pereira LR, Asensi MD. Susceptibility of clinical isolates of multiresistant Pseudomonas aeruginosa to a hospital disinfectant and molecular typing. Mem. Inst. Oswaldo Cruz. 100(5), 541-548 (2005
38. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn. Microbiol. Infect. Dis. 78(4), 443-448 (2014
39. El Zowalaty ME. Alarming trend of antibiotic resistance in Pseudomonas aeruginosa isolates. J. Pure Appl. Microbiol. 6(1), 175-183 (2012
40. Obritsch MD, Fish DN, Maclaren R, Jung R. Nosocomial infections due to multidrugresistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25(10), 1353-1364 (2005
41. Decousser J-W, Pina P, Picot F et al. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J. Antimicrob. Chemother. 51(5), 1213-1222 (2003
42. Kalai S, Jouaihia W, Mahjoubi F et al. [Pseudomonas aeruginosa: a multicentric study of antibiotic resistance (1999-2000)]. Tunis. Med. 82(12), 1070-1074 (2004
43. Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati M, Farshad S. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 32(3), 343-347 (2006
44. Fadda G, Spanu T, Ardito F et al. Antimicrobial resistance among nonfermentative Gram-negative bacilli isolated from the respiratory tracts of Italian inpatients: a 3-year surveillance study by the Italian Epidemiological Survey. Int. J. Antimicrob. Agents 23(3), 254-261 (2004
45. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J. Antimicrob. Chemother. 51(2), 347-352 (2003
46. Saiman L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis:'the motion for'. Paediatr. Respir. Rev. 8(3), 249-255 (2007
47. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004
48. Gailien? G, Pavilonis A, Kareivien? V. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups. Medicina (Kaunas) 43(1), 36-42 (2007
49. Jung R, Fish D, Obritsch M, Maclaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J. Hosp. Infect. 57(2), 105-111 (2004
50. Muthu SE, Aberna RA, Mohan V et al. Phenotypes of Isolates of Pseudomonas aeruginosa in a Diabetes Care Center. Arch. Med. Res. 37(1), 95-101 (2006
51. Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J. Microbiol. Immunol. Infect. 40(1), 45-49 (2007
52. Al-Jasser AM, Elkhizzi NA. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa. Saudi Med. J. 25(6), 780-784 (2004
53. Patzer JA, Dzier?anowska D. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993-2002). Int. J. Antimicrob. Agents 29(2), 153-158 (2007
54. Wu C-J, Lee H-C, Lee N-Y et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J. Microbiol. Immunol. Infect. 39(2), 135-143 (2006
55. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn. Microbiol. Infect. Dis. 59(4), 425-432 (2007
56. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn. Microbiol. Infect. Dis. 57(2), 207-215 (2007
57. Cavallo J, Hocquet D, Plesiat P, Fabre R, Roussel-Delvallez M. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J. Antimicrob. Chemother. 59(5), 1021-1024 (2007
58. Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 55(6), 954-957 (2005
59. Lamia T, Bousselmi K, Saida B, Allah M. [Epidemiological profile and antibiotic susceptibility of Pseudomonas aeruginosa isolates within the burned patient hospitalized in the intensive care burn unit]. Tunis. Med. 85(2), 124-127 (2007
60. Ishii Y, Alba J, Kimura S, Yamaguchi K. Evaluation of antimicrobial activity of β-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004). Diagn. Microbiol. Infect. Dis. 55(2), 143-148 (2006
61. Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey. Am. J. Infect. Contr. 34(4), 188-192 (2006
62. Al-Tawfiq JA. Occurrence and antimicrobial resistance pattern of inpatient and outpatient isolates of Pseudomonas aeruginosa in a Saudi Arabian hospital: 1998-2003. Int. J. Infect. Dis. 11(2), 109-114 (2007
63. Lee YC, Ahn BJ, Jin JS et al. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea. J. Microbiol. 45(4), 358-363 (2007
64. Tam VH, Chang K-T, Larocco MT et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 58(3), 309-314 (2007
65. Xiao M, Wang Y, Yang Q-W et al. Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints. Int. J. Antimicrob. Agents 40(5), 445-449 (2012
66. Strateva T, Ouzounova-Raykova V, Markova B, Todorova A, Marteva-Proevska Y, Mitov I. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J. Med. Microbiol. 56(7), 956-963 (2007
67. Lee Y-L, Chen Y-S, Toh H-S et al. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010. Int. J. Antimicrob. Agents 40, S29-S36 (2012
68. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48(7), 2431-2436 (2004
69. Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur. J. Clin. Microbiol. Infect. Dis. 24(3), 196-201 (2005
70. Sava? L, Duran N, Sava? N, Onlen Y, Ocak S. The prevalence and resistance patterns of Pseudomonas aeruginosa in intensive care units in a university hospital. Turkish J. Med. Sci. 35(5), 317-322 (2005
71. Brown PD, Izundu A. Antibiotic resistance in clinical isolates of Pseudomonas aeruginosa in Jamaica. Rev. Panam. Salud Publica 16(2), 125-130 (2004
72. Gad GF, El-Domany RA, Zaki S, Ashour HM. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J. Antimicrob. Chemother. 60(5), 1010-1017 (2007
73. Edwards JR, Diamantakos EA, Peuler JD, Lamar PC, Prozialeck WC. A novel method for the evaluation of proximal tubule epithelial cellular necrosis in the intact rat kidney using ethidium homodimer. BMC Physiol. 7(1), 1 (2007
74. El Mouedden M, Laurent G, Mingeot- Leclercq M-P, Taper HS, Cumps J, Tulkens PM. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob. Agents Chemother. 44(3), 665-675 (2000
75. Tsai IT, Chen YH, Chen YH, Wang YH. Amikacin-induced fin reduction is mediated by autophagy. J. Toxicol. Pathol. 26(1), 79-82 (2013
76. Duan M, Agerman K, Ernfors P, Canlon B. Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycosideinduced ototoxicity. Proc. Natl Acad. Sci. USA 97(13), 7597-7602 (2000
77. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J. Chem. Neuroanat. 10(3-4), 179-190 (1996
78. Nagai J, Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosisindependent pathways. Biochem. Pharmacol. 90(4), 331-337 (2014
79. Tanaka R, Muraki K, Ohya S. et al. TRPV4-like non-selective cation currents in cultured aortic myocytes. J. Pharmacol. Sci. 108(2), 179-189 (2008
80. Jiang M, Wang Q, Karasawa T, Koo JW, Li H, Steyger PS. Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides. PLoS ONE 9(9), e108941 (2014
81. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7), 885-888 (2003
82. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother. 33(9), 960-967 (1999
83. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrugresistant pathogens: a critical review. J. Antimicrob. Chemother. 60(6), 1206-1215 (2007
84. Gales A, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S146-S155 (2001
85. Gales A, Jones R, Sader H. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gramnegative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 12(4), 315-321 (2006
86. Pitt T, Sparrow M, Warner M, Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58(9), 794-796 (2003
87. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 49(2), 403-406 (2002
88. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6(9), 589-601 (2006
89. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 21(3), 449-465 (2008).
90. Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LFA. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob. Agents Chemother. 57(3), 1442-1446 (2013
91. Keirstead ND, Wagoner MP, Bentley P et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol. Sci. 137(2), 278-291 (2014
92. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am. J. Med. 119(6), S37-S44 (2006
93. Shimizu T, Harada K, Kataoka Y. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin. Acta Vet. Scand. 55(1), 37 (2013
94. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44(5), 681-688 (2007
95. Blondeau J, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 16(Suppl. 3), 1-19 (2004
96. Karlowsky JA, Kelly LJ, Thornsberry C et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int. J. Antimicrob. Agents 19(1), 21-31 (2002
97. Magiorakos AP, Srinivasan A, Carey R et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268-281 (2012
98. Babay HA. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005. Jpn. J. Infect. Dis. 60(2-3), 123-125 (2007
99. Goossens H. Susceptibility of multi-drugresistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin. Microbiol. Infect. 9(9), 980-983 (2003
100. Sekiguchi J-I, Asagi T, Miyoshi-Akiyama T et al. Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J. Clin. Microbiol. 45(3), 979-989 (2007
101. Anupurba S, Bhattacharjee A, Garg A, Sen MR. Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from wound infections. Ind. J. Dermatol. 51(4), 286-288 (2006
102. Wang C, Jerng J, Cheng K et al. Pandrugresistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin. Microbiol. Infect. 12(1), 63-68 (2006
103. Cabot G, Ocampo-Sosa A, Dominguez M et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob. Agents Chemother 56, 6349-6357 (2012
104. Mulet X, Cabot G, Ocampo-Sosa AA et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob. Agents Chemother. 57(11), 5527-5535 (2013
105. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 35(5), 736-755 (2011
106. Cochran W, McFeters G, Stewart P. Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J. Appl. Microbiol. 88(1), 22-30 (2000
107. Thomas L, Maillard J-Y, Lambert R, Russell A. Development of resistance to chlorhexidine diacetate in Pseudomonas aeruginosa and the effect of a'residual'concentration. J. Hosp. Infect. 46(4), 297-303 (2000
108. Romao C, Miranda CA, Silva J, Clementino MM, De Filippis I, Asensi M. Presence of qacE?1 gene and susceptibility to a hospital biocide in clinical isolates of Pseudomonas aeruginosa resistant to antibiotics. Curr. Microbiol. 63(1), 16-21 (2011
109. Tschudin-Sutter S, Frei R, Kampf G, et al. Emergence of glutaraldehyde-resistant Pseudomonas aeruginosa. Emergence 32(12), 1173-1178 (2011
110. Beier RC, Foley SL, Davidson MK et al. Characterization of antibiotic and disinfectant susceptibility profiles among Pseudomonas aeruginosa veterinary isolates recovered during 1994-2003. J. Appl. Microbiol.118(2), 326-342 (2014
111. Kampf G, Ostermeyer C, Tschudin-Sutter S, Widmer A. Resistance or adaptation?. How susceptible is a 'glutaraldehyde-resistant' Pseudomonas aeruginosa isolate in the absence of selection pressure?. J. Hosp. Infect. 84(4), 316-318 (2013
112. Pinna A, Usai D, Zanetti S, Thomas PA, Kaliamurthy J. Susceptibility of various corneal fungal isolates and Pseudomonas aeruginosa to contact lens disinfecting solutions. J. Infect. Dev. Countries 7(03), 261-268 (2013
113. O'Neill J. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations (2014). http://amr-review.org/
114. EU CDC. Annual epidemiological report 2014. Antimicrobial resistance and healthcare associated infections (2013). http://ecdc.europa.eu/en
115. WHO. Antimicrobial resistance: global report on surveillance. WHO, Geneva, Switzerland (2014). http://who.int
116. Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9(12), 894-896 (2011
117. Smith RD, Coast J. Antimicrobial resistance: a global response. Bull. World Health Organ. 80(2), 126-133 (2002
118. Brinkman FS, Bains M, Hancock RE. The amino terminus of Pseudomonas aeruginosa outer membrane protein OprF forms channels in lipid bilayer membranes: correlation with a three-dimensional model. J. Bacteriol. 182(18), 5251-5255 (2000
119. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264(5157), 382-388 (1994
120. Nikaido H. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin. Cell Devel. Biol. 12(3), 215-223 (2001
121. Lambert P. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J. R. Soc. Med. 95(Suppl. 41), 22-26 (2002
122. Achouak W, Heulin T. Multiple facets of bacterial porins. FEMS Microbiol. Lett. 199(1), 1-7 (2001
123. Dubois V, Arpin C, Melon M et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of β-lactam resistance. J. Clin. Microbiol. 39(6), 2072-2078 (2001
124. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem. Pharmacol. 60(4), 457-470 (2000
125. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere J, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J. Antimicrob. Chemother. 51(5), 1055-1065 (2003
126. Kaatz GW. Bacterial efflux pump inhibition. Curr. Opin. Invest. Drugs (Lond.) 6(2), 191-198 (2005
127. Kamicker BJ, Sweeney MT, Kaczmarek F et al. Bacterial efflux pump inhibitors. In: Methods in Molecular Medicine (Volume 142): New Antibiotic Targets. Champney WS (Ed.). Humana Press Inc., NJ, USA. Springer, 187-204 (2008
128. He G-X, Kuroda T, Mima T, Morita Y, Mizushima T, Tsuchiya T. An H+-coupled multidrug efflux pump, PmpM, a member of the MATE family of transporters, from Pseudomonas aeruginosa. J. Bacteriol. 186(1), 262-265 (2004
129. Mcmurry L, Petrucci RE, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc. Natl Acad. Sci. USA 77(7), 3974-3977 (1980
130. Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob. Agents Chemother. 44(9), 2233-2241 (2000
131. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19(2), 382-402 (2006
132. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39(3), 162-176 (2007
133. Piddock LJ. Multidrug-resistance efflux pumps?. not just for resistance. Nat. Rev. Microbiol. 4(8), 629-636 (2006
134. Webber M, Piddock L. The importance of efflux pumps in bacterial antibiotic resistance. J. Antimicrob. Chemother. 51(1), 9-11 (2003
135. Nikaido H. Multiple antibiotic resistance and efflux. Curr. Opin. Microbiol. 1(5), 516-523 (1998
136. Baugh S, Phillips CR, Ekanayaka AS, Piddock LJV, Webber MA. Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J. Antimicrob. Chemother. 69, 673-681 (2014
137. Sun J, Deng Z, Yan A et al. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453(2), 254-267 (2014
138. Evans K, Passador L, Srikumar R, Tsang E, Nezezon J, Poole K. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 180(20), 5443-5447 (1998
139. Hirakata Y, Srikumar R, Poole K et al. Multidrug efflux systems play an important 17 role in the invasiveness of Pseudomonas aeruginosa. J. Exp. Med. 196, 109-118 (2002
140. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet. Mol. Res. 2(1), 48-62 (2003
141. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 3(2), 255-264 (2001
142. Poole K. Resistance to β-lactam antibiotics. Cell. Mol. Life Sci. 61(17), 220-223 (2004
143. Poole K. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2, 65 (2011
144. Adewoye L, Sutherland A, Srikumar R, Poole K. The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J. Bacteriol.184(15), 4308-4312 (2002
145. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49(2), 479-487 (2005
146. Guenard S, Muller C, Monlezun L et al. Multiple mutations lead to MexXY-OprMdependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58(1), 221-228 (2014
147. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pages J-M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59(6), 1223-1229 (2007
148. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem. Pharmacol. 71(7), 910-918 (2006
149. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J. Mol. Microbiol. Biotechnol. 3(2), 225-236 (2001
150. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47(5), 505-511 (2001
151. Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob. Agents Chemother. 49(2), 849-852 (2005
152. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(2), 719-726 (2003
153. Renau TE, Leger R, Flamme EM et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem. 42(Issue), 4928-4931 (1999
154. Yoshida K, Nakayama K, Ohtsuka M et al. MexAB OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part7:highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg. Med. Chem. 15, 7087-7097 (2007
155. Opperman TJ, Nguyen ST. Recent advances toward a molecular mechanism of efflux pump inhibition. Frontiers Microbiol.6 (2015
156. Opperman TJ, Kwasny SM, Kim HS et al. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob. Agents Chemother. 58, 722-733 (2014
157. Opperman TJ, Nguyen ST. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol. 6, 421 (2015
158. Levy S. Active efflux, a common mechanism for biocide and antibiotic resistance. J. Appl. Microbiol. 92(s1), 65S-71S (2002
159. Zechini B, Versace I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat. Antiinfect. Drug Discov. 4(1), 37-50 (2009
160. Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem. Pharmacol. 71(7), 1085-1095 (2006
161. Vahaboglu H, Coskunkan F, Tansel O et al. Clinical importance of extended-spectrum β-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J. Med. Microbiol. 50(7), 642-645 (2001
162. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8(6), 321-331 (2002
163. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47(3), 247-250 (2001
164. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm?. Clin. Microbiol. Rev. 18(2), 306-325 (2005
165. Amin NE, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. Apmis 113(3), 187-196 (2005
166. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50(5), 1633-1641 (2006
167. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49(11), 4733-4738 (2005
168. Moya B, Dotsch A, Juan C et al. β-lactam resistance response triggered by inactivation of a nonessential penicillinbinding protein. PLoS Pathog. 5(3), e1000353 (2009
169. Vogne C, Aires JR, Bailly C, Hocquet D, Plesiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48(5), 1676-1680 (2004
170. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin. Infect. Dis. 34(5), 634-640 (2002
171. Sobel ML, Mckay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47(10), 3202-3207 (2003
172. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J. Med. Microbiol. 58(9), 1133-1148 (2009
173. Yokoyama K, Doi Y, Yamane K et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet 362(9399), 1888-1893 (2003
174. Mesaros N, Nordmann P, Plesiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13(6), 560-578 (2007
175. Russell A. Antibiotic and biocide resistance in bacteria: introduction. J. Appl. Microbiol. 92(s1), 1S-3S (2002
176. Chapman JS. Biocide resistance mechanisms. Int. Biodeter. Biodeg.51(2), 133-138 (2003
177. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J. Appl. Microbiol. 92(s1), 55S-64S (2002
178. Gilbert P, Mcbain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin. Microbiol. Rev. 16(2), 189-208 (2003
179. Hay AG, Dees PM, Sayler GS. Growth of a bacterial consortium on triclosan. FEMS Microbiol. Ecol. 36(2-3), 105-112 (2001
180. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J. Appl. Microbiol. 92(s1), 55S-64S (2002
181. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J. Bacteriol. 184(18), 5036-5044 (2002
182. Masak J, ?ejkova A, Schreiberova O, ?ezanka T. Pseudomonas biofilms: possibilities of their control. FEMS Microbiol. Ecology 89(1), 1-14 (2014
183. Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26(8), 1011-1024 (2008
184. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit. Care Med. 37(5), 1777-1786 (2009
185. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum. Vaccines 7(10), 999-1011 (2011
186. Jiang M, Yao J, Feng G. Protective effect of DNA vaccine encoding Pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS ONE 9(5), e96609 (2014
187. Saha S, Takeshita F, Sasaki S et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 24(37), 6240-6249 (2006
188. Sharma A, Krause A, Xu Y, Sung B, Wu W, Worgall S. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa. PLoS ONE 8(2), e56996 (2013
189. Staczek J, Gilleland L, Heyde H, Gilleland H. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 37(2-3), 147-153 (2003
190. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 6, CD001399 (2013
191. Krylov VN. Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy. Adv. Virus Res. 88, 227-278 (2013
192. Essoh C, Blouin Y, Loukou G et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8(4), e60575 (2013
193. Alemayehu D, Casey PG, Mcauliffe O et al. Bacteriophages ?MR299-2 and ?NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio 3(2), e00029-00012 (2012
194. Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201(7), 1096-1104 (2010
195. Krylov V, Shaburova O, Krylov S, Pleteneva E. A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 5(1), 15-53 (2012
196. Saussereau E, Debarbieux L. Chapter 4 - Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. In: Advances in Virus Research. Ma?gorzata ?, Wac?aw S (Eds). Academic Press 83, 123-141 (2012
197. Soothill J. Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections. Expert Rev. Anti. Infect. Ther. 11(9), 909-1015 (2013
198. Krom RJ, Bhargave P, Lobritz MA, Collins JJ. Engineered phagemids for nonlytic targeted antibacterial therapies. Nano. Lett. 15(7), 4808-4813 (2015
199. El Zowalaty ME, Bustin SA, Husseiny MI, Ashour HM. Avian influenza: virology, diagnosis and surveillance. Future Microbiol. 8(9), 1209-1227 (2013
200. Elshabrawy HA, Fan J, Haddad CS et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel highthroughput screening assay. J. Virol. 88(8), 4353-4365 (2014
201. Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS ONE 7(11), e50366 (2012
202. Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev. Vaccines 13(4), 507-519 (2014
203. Gad GF, El-Domany RA, Ashour HM. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt. J. Urol. 180(1), 176-181 (2008
204. Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. Int. J. Nanomedicine 6, 1463-1473 (2011
205. Taylor EN, Kummer KM, Dyondi D, Webster TJ, Banerjee R. Multi-scale strategy to eradicate Pseudomonas aeruginosa on surfaces using solid lipid nanoparticles loaded with free fatty acids. Nanoscale 6, 825-832 (2014
206. Faria AF, Martinez DST, Meira SMM et al. Anti-adhesion and antibacterial activity of silver nanoparticles supported on graphene oxide sheets. Colloids Surf. B. 113, 115-124 (2014
207. Diggikar R, Patil R, Kale S et al. Silverdecorated orthorhombic nanotubes of lithium vanadium oxide: an impeder of bacterial growth and biofilm. Appl. Microbiol. Biotechnol. 97, 8283-8290 (2013
208. Tseng LP, Juan CY, Lin SL et al. Nanohybrids of silver particles on clay platelets delaminate Pseudomonas biofilms. Nanomedicine 9(7), 10199-1033 (2014
209. Lungu M, Gavriliu S, Enescu E et al. Silver-titanium dioxide nanocomposites as effective antimicrobial and antibiofilm agents. J. Nanopart. Res.16, 2203 (2014
210. Naik K, Kowshik M. Anti-biofilm efficacy of low temperature processed AgCl-TiO2 nanocomposite coating. Mater. Sci. Eng. C34, 62-68 (2014
211. Badireddy AR, Marinakos SM, Wiesner MR, Chellam S. Lipophilic nano-bismuth inhibits bacterial growth, attachment, and biofilm formation. Surf. Innovations 1, 181-189 (2013
212. Deacon J, Abdelghany SM, Quinn DJ et al. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). J. Control. Release 198, 55-61 (2015
213. Ling LL, Schneider T, Peoples AJ et al. A new antibiotic kills pathogens without detectable resistance. Nature 517(7535), 455-459 (2015
214. Piddock LJ. The crisis of no new antibiotics - what is the way forward?. Lancet Infect. Dis. 12(3), 249-253 (2012
215. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164 (2008
216. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we?. Ann. Clin. Microbiol. Antimicrob. 12, 22 (2013
217. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same?. Br. J. Pharmacol. 163(1), 184-194 (2011
218. Lara HH, Ayala-Nunez NV, Turrent LDCI, Padilla CR. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J. Microbiol. Biotechnol. 26(4), 615-621 (2010
219. Rai M, Deshmukh S, Ingle A, Gade A. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J. Appl. Microbiol. 112(5), 841-852 (2012
220. Usman MS, El Zowalaty ME, Shameli K, Zainuddin N, Salama M, Ibrahim NA. Synthesis, characterization, and antimicrobial properties of copper nanoparticles. Int. J. Nanomedicine 8, 4467-4479 (2013
221. Mftah A, Alhassan FH, Al-Qubaisi MS et al. Physicochemical properties, cytotoxicity, and antimicrobial activity of sulphated zirconia nanoparticles. Int. J. Nanomedicine 10, 764-765 (2015
222. Martinez-Gutierrez F, Olive PL, Banuelos A et al. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine 6(5), 681-688 (2010
223. Ashraf S, Chatha MA, Ejaz W, Janjua HA, Hussain I. Lysozyme-coated silver nanoparticles for differentiating bacterial strains on the basis of antibacterial i have amended figure 1 so the colours activity. Nanoscale Res. Lett. 9(1), 565 (2014
224. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 65(13), 1803-1815 (2013
225. Allen HKS, Donato J, Wang HH, Cloud- Hansen KA, Davies J, Handelsman J. Call of the wild: antibiotic resistance genes in natural environments. Nat. Rev. Microbiol. 8(4), 251-259 (2010
226. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050 (2007